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Stem cells on South African 
shores: Proposed guidelines for 
comprehensive informed consent
To the Editor: In October 2012, Shinya Yamanaka and Sir John 
Gurdon were awarded the Nobel Prize in Physiology or Medicine 
for their pioneering research into the reprogramming of mature cells 
into a pluripotent state. The technology developed by Yamanaka 
and colleagues allows researchers to turn terminally differentiated 
somatic cells back into a stem-cell state.1 These induced pluripotent 
stem cells (iPSCs) can be cultured indefinitely in the laboratory, 
and can undergo directed differentiation into any cell type of 
interest. This is highly beneficial for disease-modelling studies, since 
researchers are able to culture cells that are not normally obtainable, 
such as neurons or retinal cells. Furthermore, the differentiated cells 
can be used to test potential therapies in patient-derived cells, and 
may even be used for future therapeutic cell transplantation.
iPSC research is no longer a ‘foreign’ technology, with laboratories 
from at least two South African institutions employing these methods 
for ‘disease-in-a-dish’ modelling. Given the seemingly endless 
possibilities for future iPSC-based research, we wish to highlight the 
challenges associated with obtaining comprehensive informed consent 
from research participants. A recent review from the National Institutes 
of Health in the USA outlined the standards, policies, protocols and 
regulations required for cell-based therapies, and addressed specimen 
collection for iPSC research.2 The authors pointed out that providing 
accurate information about what will not be done with a research 
participant’s specimen is almost impossible, given the rapid advances 
in research. We propose that the informed consent documentation 
must be explicit when addressing these matters. In South Africa, 
for example, definitive assurance could be given that germline cell 
derivatives and reproductive applications will not be attempted or 
developed with the generated iPSCs, as current legislation prohibits 
certain uses of biological samples, such as the reproductive cloning of 
humans (National Health Act 61/2003: 57(1)). These assurances will 
need to be reviewed regularly, however, so that research possibilities are 
not stultified by bureaucracy and avoidance of debate.
In many respects, iPSC research seems to provide more questions 
than answers and this creates a new challenge for researchers and 
research ethics committees.3 A balance must be found between 
consent that is too broad and indistinct, or too narrow, which may 
hinder future research prospects. Some commentators favour a 
‘tiered’ approach to consent, which allows participants to consent 
to specific uses, and to stipulate their wishes regarding banking 
and sharing their biological material with other researchers, and 
whether they wish to be re-contacted in the event that further use 
of their samples is needed. This would enable individuals to opt out 
of sensitive areas such as gamete formation, reproductive research, 
commercialisation and genetic manipulation.
In the South African context, we need to determine efficacy and 
safety by using iPSCs as pre-clinical cellular models, in preparation 
for future therapeutic development and human clinical trials. By 
addressing the scientific, legal and ethical implications of establishing 
and using iPSCs in the laboratory, we can use this time constructively 
and productively to develop prospective policies for the use of iPSCs 
in future therapeutic applications.4 
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Poor maternal outcomes
To the Editor: I was surprised to read that Schoon and Motlolometsi 
were not able to find any clear job description or scope of practice 
for advanced midwives (ADMs) in this country.1 Both were clearly 
defined in KwaZulu-Natal in 1980, when the first ADM training 
programme was established at King Edward VIII Hospital, Durban.
The programme was co-designed by the Nursing College and 
the Community Obstetrics Department of the University of Natal 
medical school. The starting points used were the needs then apparent 
in the province’s maternity services and the framework of regulations 
governing the Advanced Diploma in Midwifery and Neonatal 
Science. The scope of practice and job description were further 
developed by DEPAM (the Decentralised Education Programme for 
Advanced Midwives), funded by the Kellogg Foundation, and the 
university Department of Nursing’s postgraduate programme. Only 
competent midwives were selected for the course.
The skills base aimed at developing nurse practitioners who would 
be able to do the following, in co-operation with the medical staff:
• adequately assess the health status of antenatal, intrapartum and 
postnatal women, and their neonates
• manage patients attending the high-risk antenatal clinics for 
women with hypertension, multiple pregnancies, previous 
caesarean section, gestational diabetes, etc. 
• manage these women in labour with the assistance of the 
medical staff
• provide excellent postnatal care to 6 weeks postpartum
• monitor the standard of obstetric care, including organising 
and running monthly perinatal mortality meetings, and offer 
feedback to the district staff regarding all referrals
• provide ongoing in-service education for all midwives in the 
hospital and its referring clinics, later using the Perinatal 
Education Programme (PEP)2 material
• locate and train traditional midwives to bring them into the 
care net
• act as facilitators in building a perinatal care team in the unit.
We followed the first graduates from the diploma course back to 
their hospitals in northern KZN in 1981, and helped them to apply 
their skills there. Many of these nurse practitioners faced resistance 
from nursing managers, but most medical officers in rural units were 
grateful for their help, and bought into the concept. At that time, the 
district hospital system was fully integrated, and the ADMs were able to 
move around from each district hospital to its clinics, supporting and 
upgrading midwives’ skills. 
The impact of these enthusiastic women with medical support was 
impressive. Regional perinatal mortality dropped from 46/1 000 to 
25/1 000 and the maternal mortality rate fell to 107/100 000 in 1993, 
in spite of political turmoil in the province. 
Unfortunately, the lack of a career path in clinical nursing care meant 
that many ADMs were later ‘promoted’ to administrative posts. Their 
impact was also vastly reduced by the new Health Act, which replaced 
their passionate hands-on clinical leadership with cadre-deployment 
bureaucrats who have no direct responsibility for obstetric outcomes.
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Therein lies a lesson for those wishing to improve the lot of 
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Can a new paediatric sub-specialty 
improve child health in South Africa?
To the Editor: David Hall (my previous Professor of Child Health 
in the UK, who always hoped to make a contribution to child health 
in South Africa) and others emphasise the importance of the child 
health approach in delivering healthcare for children.1
The suggested sub-specialty would help to change the mindset of South 
African doctors from believing that paediatric care and child healthcare 
are the same. The former focuses on ill health (ubisi seluchithekile – 
‘the horse has already bolted’), while the latter would suggest a more 
comprehensive approach to the needs of children, i.e. crisis intervention, 
prevention and health promotion. The health policy of the present 
South African government implies such an approach, although serious 
management constraints have prevented implementation.
The Health Development Institute (HDI), based in Mitchell’s Plain, 
Cape Town, piloted a community-based healthcare model with a 
comprehensive approach to the provision of healthcare for children in 
backyard crèches.2 The HDI undertook a major project to assess the needs 
of these children (physical, including dental). Among other findings, the 
survey identified service gaps for this population, and made suggestions 
as to how they could be bridged. This project demonstrated a community-
based approach to healthcare of children by translating the individual 
needs of the child to the needs of the community by integrating clinical 
practice and population health. Sensitising family doctors to population 
health would also help them to appreciate the distinction between health 
inequalities (by and large influenced by personal lifestyles) and health 
inequities (influenced by social factors that require appropriate health, 
economic and educational policies to redress).3 
However, the translation of clinical encounters to a population 
approach will require a pro-active public health discipline to complement 
such a paradigm shift for these family prctitioners. Some years ago I 
raised this issue with Dr Hendrik Hanekom (then Secretary-General 
of the South African Medical Association) when I was serving on the 
Board of SAMA, suggesting the setting up of a public health consultancy 
within SAMA. Given that the objectives of SAMA include encouraging 
involvement in health promotion and education, and influencing the 
healthcare environment to meet the needs and expectations of the 
community by promoting improvements in health reform policy and 
legislation, such a sub-committee would enable SAMA to play its rightful 
role as the custodians of the nation’s health. 
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When will we escape from the medical 
funding industry’s ‘spin’?
To the Editor: I am a specialist in private practice. A patient recently 
asked for a quotation for an operation, and I supplied her with the 
relevant codes and pricing structures. As we have no contracts with 
medical aids she was advised to contact her insurer to ascertain which 
payments she could expect. Obtaining this information from them 
was a challenge. She was informed that they could not provide an 
estimate as to which part of the cost they would cover (thankfully, 
she was not regaled with the usual ‘we refund 100%, 200% and even 
300% of the bill’). She was also told that they had not heard of code 
0023, which is the anaesthetic modifier for time that must feature 
on an anaesthetic account and with which most funders are familiar.
This anecdote illustrates the wilful or unintentional incompetence 
of the medical funding industry. At the same time we are bombarded 
with media reports from the Minister of Health, the Editor of the 
SAMJ and the Board of Healthcare Funders expressing alarm at 
escalating healthcare costs and the integral part the private sector 
plays in this.
Health practitioners in private practice should have a fee structure 
as prescribed by their peers. I believe that this is the norm in other 
professions, and do not see why doctors should be treated differently. 
Fees may sometimes be dictated by harsh market forces of supply 
and demand, but certainly not by the Minister of Health, the Health 
Professions Council of South Africa, or the funding industry.
Patients are expected to pay a hefty monthly premium to an 
outside institution that promises to cover their medical costs. They 
unquestioningly accept this promise, but increasingly it remains 
unkept. However, promises broken by funders have mutated into 
overcharging by providers.
Although it is well publicised that medical aids are non-profit 
organisations, administrative profits seem to be the reason why 
medical aids such as Discovery are doing very successful business.
Has the time not come to stop the tired refrain of ‘doctors 
overcharging’ and focus on an industry that adds little of value to its 
members (patients) and is increasingly part of the problem rather than 
part of the solution?
Patients approach us for quotes, which are provided. This 
information can be studied and terms discussed with the service 
provider, a process generally well accepted by patients. When medical 
aid comes on the scene, patients expect it to cover everything and 
question why medical aid rates are not charged. The obvious response 
to this logic is that medical aids would probably not be impressed if 
doctors suggested monthly premiums they should charge!
In short: doctors and patients should discuss and negotiate fees 
between themselves. There is no need for medical aid assistance or 
interference. Patients entrust doctors with matters that may involve 
life or death. Maybe the Minister, the HPCSA and the BHF should 
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